Compare Amgen, Inc. (AMGN) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Danaos Corporation — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Danaos Corporation trades at $128.39 (market cap $2.34B). The key difference: Amgen, Inc. is far larger — about 83.8× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| AMGN | DAC | |
|---|---|---|
Market Cap | $196.12B | $2.34B |
Sector | Health | Technology |
52-Week High | $388.16 | $134.63 |
52-Week Low | $271.18 | $84.05 |
Enterprise Value | $241.41B | $2.34B |
Dividend Yield | 2.77% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DAC trades at $128.39, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 4.53, P/B of 0.6, and net income margin of 49.85%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while the company maintains a $0.90 quarterly dividend. Cash flow from operations remains robust at $645 million for 2025.
Outlook is positive given deep value metrics and high profitability, but risks include cyclical shipping demand and earnings volatility. Analyst consensus is mixed with 40% buy ratings. The stock offers value but requires monitoring of charter rate trends and global trade conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
